Latest Breaking News On - குறைக்கப்பட்டது வெளியேற்றம் பின்னம் - Page 1 : comparemela.com

Press release content from Business Wire. The AP news staff was not involved in its creation. Merck Announces U.S. FDA Approval of VERQUVO® (vericiguat) January 20, 2021 GMT KENILWORTH, N.J. (BUSINESS WIRE) Jan 20, 2021 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. The approval of VERQUVO by the FDA, which is the first treatment for chronic heart failure approved specifically for patients following a hospitalization for heart failure or need for outpatient IV diuretics, is based on the results of the pivotal Phase 3 VICTORIA trial and follows a priority regulatory review

Canada
United-states
Canadian
Michael-decarbo
Paulw-armstrong
Peter-dannenbaum
Patrick-ryan
Roy-baynes
Instagram
Bayer-ag
University-of-alberta
Merck-research-laboratories